LY518674

LY518674 is a potent, selective PPARα agonist, with an EC50 of 42 nM for human PPARα. LY518674 reduces triglycerides in and increased HDL-C and is used for the treatment of atherosclerosis[1][2][3].

Product Specifications

CAS Number

[425671-29-0]

Product Name Alternative

LY-674

UNSPSC

12352005

Target

PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/ly518674.html

Concentration

10mM

Purity

98.50

Solubility

DMSO : 250 mg/mL (ultrasonic)

Smiles

CC(C)(OC1=CC=C(CCCC2=NC(N(CC3=CC=C(C)C=C3)N2)=O)C=C1)C(O)=O

Molecular Formula

C23H27N3O4

Molecular Weight

409.48

References & Citations

[1]Bravo Y, et al. Identification of the first potent, selective and bioavailable PPARα antagonist. Bioorg Med Chem Lett. 2014 May 15;24 (10) :2267-72.|[2]Nissen SE, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA. 2007 Mar 28;297 (12) :1362-73.|[3]Khera AV, et al. Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. Eur Heart J. 2015 Nov 14;36 (43) :3020-2.